Hemophagocytic Lymphohistiocytosis
New hemophagocytic lymphohistiocytosis research, summarized each month in plain language.
2026 so far: So far in 2026 (January-September), more clinical data appeared for targeted immune medicines, especially ruxolitinib in children and rituximab in selected EBV-HLH. At the same time, combined lab and organ-risk signals were used more often to track how severe HLH might be. Read the 2026 review
We also cover clinical trials.
Yearly update
2026 so far
- Ruxolitinib-based treatment. Evidence expanded from reports to pediatric trial data.
- EBV- and IFN-targeted drugs. More trigger-specific targeting appeared in EBV-driven settings.
- Combination treatment patterns. Cohorts linked active HLH therapy to higher remission and survival.
- Organ and risk monitoring. Multiple cohorts reinforced organ-complication markers as key risks.
- Earlier and clearer diagnosis. More work combined labs, immune tests, and biopsies.
New
September 2026
- Multiple test results. Several studies investigated combinations of blood tests and immune-cell measurements as possible ways to assess HLH, while others examined individual markers.
- Child risk groups. A combined model helped separate higher- from lower-risk children.
- Admission lab risks. Higher bilirubin and very high ferritin were tied to worse survival.
- Checkpoint inhibitor HLH. Reports showed treatment responses, but deaths also occurred.
August 2026
- Common treatments. Steroids plus trigger treatment was common, with mixed responses.
- Early warning signs. Simple scoring tools flagged possible HLH, but need wider testing.
- Ferritin signal. In very ill children, ferritin separated HLH better than one immune marker.
- Brain and spine. Early nervous system signs and abnormal spinal fluid linked to worse survival.
July 2026
- Late hospital diagnosis. HLH was sometimes diagnosed after discharge, with higher death rates.
- Conditions that mimic HLH. Infections or inflammation sometimes explained HLH-like findings instead.
- Early warning tests. Some tests may speed recognition in certain settings.
- Emapalumab add-on therapy. In one cohort, some children reached remission with emapalumab added.
June 2026
- Ruxolitinib regimen. In one study, newly diagnosed children often reached remission by 8 weeks.
- EBV-HLH screening. Early routine hospital data helped separate EBV-HLH from mono.
- Early danger signs. Early deaths tracked with age, low platelets, and organ-stress markers.
- Transplant timing. Transplant results looked better when HLH was quiet beforehand.
May 2026
- Targeted testing for diagnosis. The cause behind HLH was easier to find when blood-marker patterns were paired with targeted sampling (for example, repeat tissue review or imaging-guided biopsy).
- Cytokines as tracking signals. Some cytokine patterns changed with disease activity, but they are not yet proven for routine clinical use.
- Combination immune treatment. In some real-world cohorts, combination immune-calming treatment (sometimes with chemotherapy) was linked to higher response than supportive care alone.
- Short-term risk markers. Older age and certain blood-test results were linked to worse short-term survival.
April 2026
- Immune-targeting medicines. In the reported groups, ruxolitinib and rituximab were associated with clinical responses.
- Ruxolitinib-first approach. One pediatric plan started with ruxolitinib and aimed to reduce early exposure to chemotherapy and steroids.
- Early risk signals. In SFTS, a risk model used early routine clinical and lab findings to flag possible HLH.
March 2026
- Common triggers. Across reports, infections and immune-system disruption repeatedly appeared as triggers for HLH.
- Identify the infection. When the specific infection was identified, what seemed to help often differed from cases without a clear cause.
February 2026
- Infection links. More infections were reported with HLH, mostly single-patient cases.
- HLH in cancer care. HLH was reported during immune cancer drugs and lymphoma treatment.
- Brain and eye signs. Brain or eye findings were linked to shorter survival in some groups.
- Immune activity tests. Some lab methods tracked immune over-activation, but routine use is unclear.
January 2026
- Cancer-related HLH. Early outcomes varied by first treatment in NK-cell cancers.
- ICU care options. Blood-filter devices were reported, but added benefit is uncertain.
- Higher-risk patterns. Clotting problems and brain involvement were repeatedly tied to higher risk.
Get the monthly update by email
Subscribe here to receive an email when a new monthly hemophagocytic lymphohistiocytosis update is published. You can unsubscribe at any time. Your address is used for this only; delivery is handled by MailerLite (privacy policy).